Immune Resilience & Post-Viral Stack
Thymosin α1 and Thymalin identity. Zadaxin is not a US NDA. This is not a viral-pathogenesis or thymic-regeneration treatment page.
Full stacking map, tiers, and monitoring notes live on the protocol page — this hub only lists the compounds already named for this goal.
Compounds on this goal
Thymosin Alpha-1
recoveryThymalfasin (Zadaxin) is an orphan-designated product with an international hepatitis story. Gray-market TA-1 is not that label.
Open peptide leaf →Thymalin
longevityKhavinson bioregulator peptide that penetrates the thymus directly, upregulating gene expression to reverse thymic involution and restore baseline immune capacity.
Open peptide leaf →LL-37
recoveryEndogenous antimicrobial peptide (cathelicidin) acting as the body's first line of defense against bacterial, viral, and fungal pathogens, while recruiting immune cells to infection sites.
Open peptide leaf →KPV
recoveryUltra-potent natural tripeptide that regulates mast cells and drives down systemic inflammation without suppressing the immune system's ability to fight pathogens.
Open peptide leaf →Thymopentin
immuneTP-5 (Arg-Lys-Asp-Val-Tyr) thymopoietin fragment. Historical immune research — not thymosin alpha-1 and not Thymalin.
Open peptide leaf →Evidence note on this goal
Protocol evidence level (from existing goal data): Moderate
- Zadaxin (TA-1) is approved internationally but not FDA-approved for general immune enhancement in the US
- Thymalin data primarily from Khavinson group; independent replication limited
- Optimal cycling protocols (frequency, duration) not established in rigorous RCTs
- Use in active autoimmune disease requires careful risk-benefit assessment (may exacerbate)